Introduction
============

Ulcerative colitis (UC) is a chronic and incurable autoimmune inflammatory bowel disorder characterized by continuous inflammation and ulceration of the mucosa of the rectum and, to a variable extent, the colon.[@b1-ppa-12-1193],[@b2-ppa-12-1193] The disease affects 2.5 million people worldwide and is usually diagnosed when individuals are in their 20s and peaks again in their 60s or 70s, but it can occur at any age. UC is generally characterized by flares that alternate with periods of remission, although some patients have continuous activity. The severity of flares and their response to treatment are difficult to predict, although the frequency of flares decreases with time. Between 25% and 40% of people living with UC will require surgery at some point in their life.[@b1-ppa-12-1193]

Simponi^®^ (golimumab, MSD, Janssen Biotech, Inc., Horsham, PA, USA) is a fully human monoclonal antibody against tumor necrosis factor α (TNF-α) available in the European Union since 2013 for the treatment of moderate-to-severe active UC in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies.[@b3-ppa-12-1193] Golimumab is also indicated for the treatment of moderate-to-severe active rheumatoid arthritis (RA) (in combination with methotrexate), active psoriatic arthritis (alone or in combination with methotrexate), and active ankylosing spondylitis.

Golimumab is administered with the SmartJect^®^ autoinjector (MSD, Janssen Biotech, Inc.) or with a prefilled syringe ([Figure 1](#f1-ppa-12-1193){ref-type="fig"}). The SmartJect autoinjector was developed to simplify self-injection of golimumab for patients suffering from RA, psoriatic arthritis, and ankylosing spondylitis, with the objective of optimizing treatment adherence.[@b4-ppa-12-1193] Autoinjectors offer several advantages, including portability, convenience, and flexible scheduling, and they have been shown to improve treatment adherence.[@b5-ppa-12-1193]--[@b7-ppa-12-1193] In the GO-MORE study, which examined the efficacy and safety of golimumab in biologic-naive RA patients, two-thirds of those who self-injected chose to use the autoinjector over a prefilled syringe.[@b4-ppa-12-1193] In addition, most of the patients using the autoinjector had a favorable impression of it, considered it easy to use, and reported that it caused little pain or discomfort. Device preferences for UC patients, however, have not been reported and may be different from RA patients who often suffer from hand pain, swelling, and deformities. Here, we report the results of a study examining whether patients with moderate-to-severe UC prefer administration of golimumab using the SmartJect autoinjector or a prefilled syringe.

Patients and methods
====================

Study design
------------

This was a multicenter, open-label, randomized, crossover trial comparing preference for administration of golimumab using the SmartJect autoinjector or a prefilled syringe in patients with moderate-to-severe UC (EudraCT no 2014-000656-29). The trial was conducted at 20 sites in Belgium (19 sites recruited patients) between July 2014 and October 2015. The primary objective was to determine whether UC patients prefer to administer golimumab using the autoinjector, using a prefilled syringe, or are undecided. Secondary objectives were to determine which of the 2 administration devices patients consider the easiest to use and result in the least discomfort, and how patient characteristics influence device preference.

The study included adults with an established diagnosis of UC and moderate-to-severe disease (Mayo score ≥6, including an endoscopic subscore ≥2) and a previous conventional therapy of at least 3 months with aminosalicylates and at least 3 months with corticosteroids, 6-mercaptopurine, or azathioprine unless intolerant to or contraindicated for such therapies. Individuals who previously self-injected any agent or who were using other biological agents were excluded.

Patients completed a questionnaire to collect demographic data, and investigators collected information about the patient's medical history. Patients were then randomized 1:1 to receive 2 injections of golimumab 50 mg (Simponi^®^, MSD) with the autoinjector (SmartJect^®^, MSD) followed by 2 injections of 50 mg with the prefilled syringe or 2 injections of 50 mg golimumab with the prefilled syringe followed by 2 injections with the autoinjector (total 200 mg golimumab administered). All injections were subcutaneous, were in the same part of the body, and were performed on the same day (day 0). The first of the 2 injections with each device was performed by the physician, and the second by the patient under the physician's supervision.

Immediately after using each device, patients answered a questionnaire assessing the hand used to self-inject (left, right, both), ease of use for self-injection (extremely easy, easy, neither easy nor difficult, difficult, or extremely difficult), overall discomfort (none, mild, moderate, severe, or such discomfort that I cannot inject future doses), and overall impression of the self-injection experience (extremely favorable, favorable, neither favorable nor unfavorable, unfavorable, or extremely unfavorable). After completing all 4 injections, patients completed a questionnaire on their preference for the devices (prefilled syringe, autoinjector, or undecided). After 2 weeks, the patient was contacted to complete the device preference questionnaire again to capture the effect of any delayed adverse events on the patient's responses.

Investigators recorded adverse events according to the International Conference on Harmonization Guidelines for Good Clinical Practice including the following: adverse event/diagnosis; dates of onset and resolution; severity (mild, moderate, severe), whether the event was serious (yes/no) and, if so, why; potential relationship to the study drug (yes/no); and action taken. Adverse events were considered serious if they resulted in death, were life threatening, required hospitalization or prolongation of an existing inpatient hospitalization, resulted in a persistent or significant disability or incapacity, were a congenital abnormality or birth defect, were cancer, were associated with an overdose, or were any other important medical event.

Ethics
------

The study was approved by each site's independent ethics committee ([Table S1](#SD1-ppa-12-1193){ref-type="supplementary-material"}) and was conducted in accordance with International Conference on Harmonization Guideline for Good Clinical Practice. All included patients provided written informed consent.

Study size estimate
-------------------

A power calculation was not performed. Instead, a study size estimate of 100 subjects was planned based on sample sizes that yielded relevant results in similar studies.[@b8-ppa-12-1193]--[@b11-ppa-12-1193] Assuming 10% dropout, approximately 110 subjects were to be screened.

Statistical analysis
--------------------

The primary outcome measure (device preference) was analyzed in the per-protocol set, defined as all subjects who met the inclusion and exclusion criteria, received all 4 injections, and completed the device preference questionnaire. Statistical analyses of preference included frequency distribution overall immediately and 2 weeks after injection; by order of device administration; 2 weeks after injection by preference immediately after injection; and by age, sex, ethnicity, marital status, education level, employment status, and total Mayo score category. Statistical analysis of secondary outcome measures (ease of use, discomfort, and overall impression) included frequency distribution overall and by order of injection. As stipulated in the study protocol, only descriptive statistics were calculated, although in a post hoc analysis, preferences were analyzed according to subject baseline characteristics by Cochrane--Armitage trend test or Fisher's exact test, with *p*-values below 0.05 considered to indicate statistical significance. Missing data were not replaced. Calculations were made using SAS version 9.2 (SAS Institute, Cary, NC, USA).

Results
=======

Patients
--------

Between July 11, 2014, and September 17, 2015, 100 patients were included in the study, and the study was completed on October 5, 2015. Of the 100 recruited patients, 99 were treated. Another 8 patients did not fulfill the selection criteria. Thus, 91 patients were included in the analysis. Most of these patients were between 30 and 60 years of age, slightly more than half were male, and all but 2 were White/Caucasian ([Table S2](#SD2-ppa-12-1193){ref-type="supplementary-material"}). On average, patients had been diagnosed with UC for 8.6 years. Disease severity was moderate in about two-thirds and severe in about one-third, although precise proportions depended slightly on the assessment (Mayo score, physician's global assessment, and sigmoidoscopic and endoscopic findings). Most were being treated with 5-aminosalicylic acid and corticosteroids, and most had not previously received anti-TNF therapy.

Device preference
-----------------

Immediately after injections, approximately three-quarters of patients (76.9%) indicated that they preferred administering golimumab with the autoinjector ([Figure 2](#f2-ppa-12-1193){ref-type="fig"}). This was similar to the preference reported 2 weeks later, with 71.4% reporting that they preferred the autoinjector. This was also the case irrespective of the order of injection, although more patients who started with the autoinjector preferred it (84.4%) than patients who started with the prefilled syringe (69.6%). Also, most patients (92.3%) did not change their preference 2 weeks later: of those who preferred a prefilled syringe immediately after the injections, all still preferred it 2 weeks later, and of those that preferred the autoinjector immediately after the injections, 92.9% still preferred it 2 weeks later. Results were similar when analyzed for all 99 patients completing the questionnaire (data not shown). A post hoc analysis showed that preference for the autoinjector was not significantly affected by patient age, disease severity as measured by the total Mayo score, sex, marital/cohabitation status, level of education, employment status, or time since UC diagnosis (data not shown).

Ease of use, discomfort, and overall impression of the devices
--------------------------------------------------------------

More patients considered the autoinjector extremely easy or easy to use (94.5%) than the prefilled syringe (73.6%) ([Table 1](#t1-ppa-12-1193){ref-type="table"}). Moderate discomfort or worse was reported by only 5 patients (5.5%) when using the autoinjector but by 19 patients (20.9%) when using the prefilled syringe. Severe discomfort or discomfort such that the patient could not inject future doses was reported by 8 patients (8.8%) when using the prefilled syringe but was not reported by any of the patients using the autoinjector.

In agreement with these findings, 89.0% of patients had an overall extremely favorable or favorable impression of the autoinjector, while 72.5% had an extremely favorable or favorable impression of the prefilled syringe. An unfavorable impression of the device or worse was reported by only 2 patients (2.2%) when using the autoinjector but by 8 patients (8.8%) when using the prefilled syringe.

The order of use of the 2 different devices appeared to slightly bias the subjects toward the device they used first. For example, the proportion of patients with an extremely favorable or favorable impression of the autoinjector was 93.3% when it was used first vs 84.8% when it was used second. Likewise, the proportion of patients with an extremely favorable or favorable impression of the prefilled syringe was 84.8% when it was used first vs 60.0% when it was used second.

Safety
------

None of the patients experienced a serious adverse event. Treatment-emergent adverse events, all mild or moderate in severity, were reported by 10 patients (10.1%) ([Table S3](#SD3-ppa-12-1193){ref-type="supplementary-material"}). These events included injection-site hematoma (n=2), injection-site pain (n=1), palpitations (n=1), UC flare (n=1), dyspepsia (n=1), flatulence (n=1), hemorrhoidal hemorrhage (n=1), tooth sensitivity (n=1), parotid gland enlargement (n=1), viral upper respiratory tract infection (n=1), headache (n=1), and hot flush (n=1).

Discussion
==========

This study showed that most patients with moderate-to-severe UC preferred to self-administer golimumab with the autoinjector over a prefilled syringe. More patients found the autoinjector easier to use and to less often cause discomfort than the prefilled syringe. This preference for the autoinjector did not change when measured again 2 weeks later, during which time most delayed reactions would have appeared. Demographic characteristics did not significantly affect preference. Order of presentation did not affect the overall preference for the autoinjector, although it biased the preference somewhat toward the device first presented. The results of this study are strengthened by the fact that data were collected in a real-life clinical setting at multiple sites. In addition, although the absolute sample size was small, this study included a relatively large population for UC and was enough to observe meaningful differences in preference.

Overall opinions were also favorable in the GO-MORE trial, in which patients with active RA self-injected or had someone else administer subcutaneous golimumab with the same device.[@b4-ppa-12-1193] Although individuals with RA often suffer from hand pain, swelling, and deformities, in GO-MORE, two-thirds of patients who chose to self-inject selected the autoinjector over a prefilled syringe. Most of the patients in the GO-MORE study who used the autoinjector had a favorable impression of it, considered it easy to use, and reported that it caused little pain or discomfort. However, the study did not directly assess preference or compare patient experiences between the autoinjector and injection with the prefilled syringe. A preference for the golimumab autoinjector over previous injection devices was also reported by 70.6% of patients in the GO-SAVE trial, which included patients with active RA who were switched from adalimumab or etanercept to golimumab.[@b12-ppa-12-1193]

Prefilled pens or other autoinjectors are also preferred over and considered easier to use and less painful than syringes for self-administration of darbepoetin by chronic kidney disease patients,[@b11-ppa-12-1193] methotrexate[@b13-ppa-12-1193] and adalimumab[@b14-ppa-12-1193] for RA patients, and insulin for diabetes patients.[@b15-ppa-12-1193]--[@b18-ppa-12-1193] Similarly, a study in healthy volunteers found that subcutaneous injection by autoinjector was preferred over syringe injection by a nurse.[@b19-ppa-12-1193]

A systematic review in 2013 found that treatment adherence to anti-TNF biologics in UC patients was only 52.7%.[@b20-ppa-12-1193] It also found that administration with a syringe vs a pen was a predictor of nonadherence. Although the SmartJect autoinjector might therefore be expected to improve adherence to golimumab, we did not assess adherence in this study.

Conclusion
==========

This study showed that patients with UC generally prefer to administer golimumab with an autoinjector. Although this should help inform prescribers about what their patients may expect, they should be aware that some patients might still prefer using a prefilled syringe.
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List of participating ethics committees

  --------------------------------------------------------------------------
  **UZ Leuven**
  **Commissie Medische Ethiek**
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  B-3000 Leuven
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  **AZ Groeninge, Campus Loofstraat**
  **Commissie Medische Ethiek**
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  2650 Edegem
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  Email <ethisch.comite@uza.be>
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  **Comité d'Ethique Hospitalo-Facultaire Universitaire de Liège**
  Professeur V. Seutin
  Centre Hospitalier Universitaire du Sart Tilman, B35
  4000 Liège
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  **Sint Augustinus (GZA Ziekenhuizen)**
  **Commissie Medische Ethiek**
  Professor Bart Van den Eynden
  Sint-Vincentiusstraat 20
  2018 Antwerpen
  Tel: 03 443 45 58 Fax 03 239 23 23
  Email <hilde.poulissen@gza.be>
  **Zol Genk, Campus St Jan**
  **Comité Medische Ethiek**
  Doctor Patrick Noyens
  Schiepse Bos 6
  3600 Genk
  Tel: 089 32 16 02 Fax 089 32 79 00
  Email <ec.submission@zol.be>
  **AZ ST Jan Brugge**
  **Commissie Medische Ethiek**
  Doctor Ludo Vanopdenbossch
  Ruddershove 10
  8000 Brugge
  Tel: 050 45 99 42 Fax 050 45 30 57
  Email <ethisch.comite@azsintjan.be>
  **UCL St Luc**
  **Commission d'Ethique Biomédicale Hospitalo-Facultaire de l'UCL**
  Professor J.M. Maloteaux
  Avenue Hippocrate 55.14, Tour Harvey, niveau 0
  1200 Bruxelles
  Tel: 02 764 55 14 Fax 02 764 55 13
  Email <commission.ethique@md.ucl.ac.be>
  **CHC St Joseph Liège**
  **Comité d'ethique médicale des cliniques St Joseph**
  Doctor René Stevens
  Rue de Hesbaye 75
  4000 Liège
  Tel: 04 224 89 90 Fax 04 229 89 92
  Email <rene.stevens@chc.be>
  **La citadelle de Liège**
  **Comité d'ethique médicale**
  Professeur François DAMAS
  Boulevard du 12ème de Ligne, 1
  4000 Liège
  Tel: 04 225 69 35 Fax 04 225 76 41
  Email <marie.louise.frenay@chrcitadelle.be>
  **OLV ziekenhuis Aalst**
  **Ethisch Comité OLV Ziekenhuis**
  Doctor Antoon Leloup
  Moorselbaan 164
  9300 Aalst
  Tel: 053 72 46 60 Fax 053 72 46 89
  Email <antoon.leloup@olvz-aalst.be>
  **Hôpital Erasme**
  **Comité d'Ethique**
  Prof. Dr. André Herchuelz
  Route de Lennik 808
  1070 Bruxelles
  Tel: 02-555 37 07 Fax 02-555 46 20
  Email <comite.ethique@erasme.ulb.ac.be>
  **GHDC, Saint-Joseph, Charleroi**
  **Comité d'Ethique Hospitalier, Grand Hopital de Charleroi**
  Mrs Laurence Gillard
  **Grand Rue 3**
  6000 Charleroi
  Tel: 071 10 43 30 Fax 071 10 85 96
  Email <duthoy.audrey@ghdc.be>
  **ZNA Jan Palfijn Antwerpen**
  Dr. P.P. De Deyn
  **Commissie voor Medische Ethiek ZNA**
  ZNA Koningin Paola Kinderziekenhuis (P6-lokaal 617)
  Lindendreef 1, 2020 Antwerpen
  Tel: 03/280.34.29 of 03/280.34.28 Fax 03/280.30.60
  Email <ethische.commissie@zna.be>
  **Centre Hospitalier de Wallonie picarde -- CHwapi A.S.B.L. Site Union**
  Dr. Luc Desplanque
  **Comité d'Ethique**
  39, Boulevard Lalaing
  7500 Tournai
  Tel: 069 33 17 56 Fax 069 25 86 54
  Email <luc.desplanque@chwapi.be>/<nathalie.mat@chwapi.be>
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  **Virga Jesse ziekenhuis, Hasselt**
  Dr. Koen Magerman
  **Ethische Toetsingscommissie Virga Jesse**
  Stadsomvaart 11
  3500 Hasselt
  Tel: 011/30.91.11 Fax 011/30.91.18
  Email <ethische.toetsingscommissie@virgajesse.be>
  CHR Peltzer La Tourelle
  Dr. Hassan Kalantari
  **Comité d'Ethique**
  Rue du Parc 29
  4800 Verviers
  Tel: 087/21 21 71 Fax 087/21.21.39
  Email <comite.ethique@chplt.be>
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  Dr. J. Vander Sande
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  Edgard Tinellaan 1c
  2800 Mechelen
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  Dr. Guy Fonteyn
  **Ethisch Comité**
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  8400 Oostende
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  Sint-Lucaslaan 29
  8310 Brugge
  Tel: +32 50 36 56 91 Fax +32 50 36 56 95
  Email <nancy.vanavermaete@stlucas.be>
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###### 

Patient demographic characteristics

  Characteristic                                          Value
  ------------------------------------------------------- -------------
  Number included in the per-protocol analysis            91
  Age (years)                                             
   Mean (SD)                                              42.7 (14.4)
   Range                                                  19.7--93.7
  Sex, n (%)                                              
   Male                                                   54 (59.3)
   Female                                                 37 (40.7)
  Ethnicity, n (%)                                        
   White/Caucasian                                        89 (97.8)
   Other                                                  2 (2.2)
  Marital status, n (%)                                   
   Single                                                 23 (25.3)
   Married/living together                                67 (73.6)
   Widow                                                  1 (1.1)
  Highest education level, n (%)                          
   Primary education                                      6 (6.6)
   Vocational secondary education                         13 (14.3)
   Technical secondary education                          13 (14.3)
   General secondary education -- humanities              12 (13.2)
   Higher education (graduate/nonuniversity)              30 (33.0)
   Higher education (university)                          17 (18.7)
  Professional status, n (%)                              
   Student                                                9 (9.9)
   Working full time                                      48 (52.7)
   Working part time                                      11 (12.1)
   Not working                                            23 (25.3)
  Time since UC diagnosis (y)                             
   Mean (SD)                                              8.6 (8.8)
   Range                                                  0.0--38.1
  Most frequent concomitant conditions (≥3%), n (%)       
   Arthritis                                              4 (4.4)
   Arthralgia                                             4 (4.4)
   Psoriasis                                              3 (3.3)
   Primary sclerosing cholangitis                         3 (3.3)
   Other                                                  6 (6.6)
  Previous exposure to anti-TNF, n (%)                    
   Naive                                                  76 (83.5)
   Experienced                                            15 (16.5)
  Concomitant medications, n (%)                          
   5-Aminosalicylic acid                                  68 (74.7)
   Corticosteroids                                        59 (64.8)
   Azathioprine                                           37 (40.7)
   Other                                                  2 (2.2)
  Total Mayo score                                        
   Mean (SD)                                              8.8 (1.6)
   Min, max                                               6, 12
  Total Mayo score categories, n (%)                      
   6                                                      7 (7.9)
   7--9                                                   49 (55.1)
   ≥10                                                    33 (37.1)
  Stool frequency, n (%)                                  
   Normal                                                 0 (0.0)
   1--2 stools more than normal                           6 (6.7)
   3--4 stools more than normal                           41 (45.6)
   5 or more stools more than normal                      43 (47.8)
  Rectal bleeding, n (%)                                  
   No blood seen                                          6 (6.7)
   Streaks of blood with stools less than half the time   27 (30.0)
   Obvious blood with stool most of the time              37 (41.1)
   Blood alone passed                                     20 (22.2)
  Physician's global assessment, n (%)                    
   Normal                                                 0 (0.0)
   Mild disease                                           4 (4.4)
   Moderate disease                                       65 (72.2)
   Severe disease                                         21 (23.3)
  Sigmoidoscopic/endoscopic findings, n (%)               
   Normal or inactive disease                             0 (0.0)
   Mild disease                                           1 (1.1)
   Moderate disease                                       54 (60.7)
   Severe disease                                         34 (38.2)

**Abbreviations:** UC, ulcerative colitis; TNF, tumor necrosis factor.

###### 

Treatment-emergent adverse events

  Adverse event                             Severity   Patients   Onset (time after injections)   Potentially related   Action taken   Resolution (time after onset)
  ----------------------------------------- ---------- ---------- ------------------------------- --------------------- -------------- -------------------------------
  Injection-site hematoma                   Mild       1          1 day                           Yes                   None           6 days
  Mild                                      1          2 days     No                              None                  12 days        
  Injection-site pain                       Mild       1          6 days                          Yes                   None           Ongoing
  Palpitations                              Mild       1          3 days                          No                    None           1 day
  Flatulence                                Moderate   1          6 days                          No                    None           3 months
  Dyspepsia                                 Mild       1          10 days                         No                    Medication     3 months
  UC flare                                  Moderate   1          1 day                           Yes                   Medication     2 months
  Viral upper respiratory tract infection   Mild       1          1 day                           Yes                   None           
  Headache                                  Mild       1          3 days                          Yes                   Medication     Ongoing
  Hot flushes                               Mild       1          1 day                           Yes                   None           Ongoing
  Hemorrhoidal hemorrhage                   Mild       1          9 days                          No                    None           Ongoing
  Tooth sensitivity                         Mild       1          6 days                          Yes                   None           Ongoing
  Parotid gland enlargement                 Mild       1          12 days                         No                    Echography     1 month

**Abbreviation:** UC, ulcerative colitis.
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![Golimumab injection devices.\
**Notes:** (**A**) SmartJect autoinjector. (**B**) Prefilled syringe.](ppa-12-1193Fig1){#f1-ppa-12-1193}

![Device preference.\
**Notes:** Patient preference for the different devices was assessed immediately after the injections and 2 weeks later. (**A**) Device preference according to order of presentation immediately after the injections. (**B**) Device preference according to order of presentation 2 weeks after the injections. (**C**) Device preference at week 2 according to preference immediately after the injections. (**D**) Device preference immediately after the injections according to age group. (**E**) Device preference immediately after the injections according to Mayo score at baseline.](ppa-12-1193Fig2){#f2-ppa-12-1193}

###### 

Ease of use, discomfort, and overall impression of the devices

  Assessment                                            Category              Autoinjector   Prefilled syringe                                       
  ----------------------------------------------------- --------------------- -------------- ------------------- ----------- ----------- ----------- -----------
  Ease of use of self-injection                         Extremely easy        27 (60.0)      26 (56.5)           53 (58.2)   9 (20.0)    15 (32.6)   24 (26.4)
  Easy                                                  17 (37.8)             16 (34.8)      33 (36.3)           20 (44.4)   23 (50.0)   43 (47.3)   
  Neither easy nor difficult                            1 (2.2)               1 (2.2)        2 (2.2)             11 (24.4)   5 (10.9)    16 (17.6)   
  Difficult                                             0 (0.0)               1 (2.2)        1 (1.1)             2 (4.4)     1 (2.2)     3 (3.3)     
  Extremely difficult                                   0 (0.0)               2 (4.3)        2 (2.2)             3 (6.7)     2 (4.3)     5 (5.5)     
  Discomfort during self-injection                      No discomfort         27 (60.0)      29 (63.0)           56 (61.5)   11 (24.4)   24 (52.2)   35 (38.5)
  Mild discomfort                                       17 (37.8)             13 (28.3)      30 (33.0)           20 (44.4)   17 (37.0)   37 (40.7)   
  Moderate discomfort                                   1 (2.2)               4 (8.7)        5 (5.5)             9 (20.0)    2 (4.3)     11 (12.1)   
  Severe discomfort                                     0 (0.0)               0 (0.0)        0 (0.0)             3 (6.7)     0 (0.0)     3 (3.3)     
  Such discomfort that I cannot inject future doses     0 (0.0)               0 (0.0)        0 (0.0)             2 (4.4)     3 (6.5)     5 (5.5)     
  Overall impression of the self-injection experience   Extremely favorable   17 (37.8)      26 (56.5)           43 (47.3)   8 (17.8)    18 (39.1)   26 (28.6)
  Favorable                                             25 (55.6)             13 (28.3)      38 (41.8)           19 (42.2)   21 (45.7)   40 (44.0)   
  Neither favorable nor unfavorable                     3 (6.7)               5 (10.9)       8 (8.8)             13 (28.9)   4 (8.7)     17 (18.7)   
  Unfavorable                                           0 (0.0)               2 (4.3)        2 (2.2)             3 (6.7)     1 (2.2)     4 (4.4)     
  Extremely unfavorable                                 0 (0.0)               0 (0.0)        0 (0.0)             2 (4.4)     2 (4.3)     4 (4.4)     

**Note:** Data presented as n (%).
